Pharmaceutical Pouch Oxygen Barrier Layer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing secondary packaging for medical liquids, particularly parenteral nutritional solutions, faces issues with oxygen migration and the contamination of medicinal liquids due to undesirable substances like cyclic diethylene glycol adipate from the packaging materials, especially in pediatric applications where the surface-to-volume ratio is high.
Innovation Solution
A secondary packaging design featuring a film with an oxygen barrier layer made of metal or semimetal oxides, sandwiched between adhesive layers, and a polyolefin inner layer, reducing the migration of undesirable substances by minimizing adhesive exposure to the primary packaging.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Strength
If a multi-layered film with adhesive layers is used for secondary packaging, then the mechanical stability and tear-open properties are improved, but the migration of undesirable substances like cyclic diethylene glycol adipate into the primary packaging increases
Solution Approach 1:
The patent introduces an oxygen barrier layer as an intermediary substance between the adhesive layer and the primary packaging. This barrier layer prevents direct contact between the adhesive (source of harmful substances) and the medical liquid, while still allowing the adhesive to fulfill its bonding function. The barrier layer acts as a mediator that blocks the migration path of cyclic diethylene glycol adipate without compromising the mechanical integrity of the multi-layered film structure.
2Manufacturing precision
If the secondary packaging has a small internal volume for pediatric applications, then the dosage precision is improved, but the surface area to volume ratio increases leading to higher migration of undesirable substances
Solution Approach 1:
The patent applies the oxygen barrier layer specifically at the critical interface where adhesive layers contact the primary packaging, rather than uniformly throughout the entire secondary packaging structure. This localized application addresses the migration problem at the specific location where harmful substances originate, while maintaining the appropriate surface area to volume ratio for pediatric dosage precision.
3Ease of manufacture
If adhesive layers are used to bond plastic film layers, then the ease of manufacture is improved, but the contamination of medical liquid with adhesive-derived substances increases
Solution Approach 1:
The oxygen barrier layer serves as an intermediary between the adhesive and the medical liquid, allowing the adhesive to perform its bonding function while preventing it from contaminating the medical product. The barrier layer is positioned between the adhesive layer and the primary packaging, creating a protective interface that maintains manufacturing simplicity while eliminating contamination risks.
4Strength
If polypropylene film is used for primary packaging, then the mechanical stability is improved, but the oxygen barrier properties deteriorate
Solution Approach 1:
The patent creates a composite structure by combining polypropylene film (for mechanical stability) with an oxygen barrier layer (for oxygen protection). The multi-layered construction integrates materials with complementary properties: polypropylene provides structural integrity and ease of processing, while the oxygen barrier layer provides the necessary oxygen protection. This composite approach allows each material to perform its optimal function without compromising the other.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This configuration effectively reduces oxygen migration and contamination, ensuring the sterility and quality of medical liquids by minimizing the exposure of undesirable substances to the medicinal products, particularly in pediatric packaging where space is limited.
Implementation Method 1
the secondary packaging must contain at least one oxygen barrier layer to reduce the migration of oxygen towards the primary packaging
Implementation Method 2
the use of an oxygen barrier layer to reduce the migration of cyclic diethylene glycol adipate
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The disclosure describes a secondary packaging in the form of a pouch for a pharmaceutical product. The secondary packaging is formed from a film comprising an outer and an inner layer. The film includes an oxygen barrier layer made of a metal and/or semimetal oxide, wherein the film comprises at least three layers, a first inner layer being a polyolefin, in particular a polypropylene, followed by a second and a third layer of a plastic towards the outer layer. The three layers are bonded by means of a first adhesive layer and a second adhesive layer. The oxygen barrier layer is arranged between the first adhesive layer and the second adhesive layer.